Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health... Show more
Philips stands as a leader in the health technology sector, organized around three core segments: Diagnosis & Treatment, Connected Care, and Personal Health. The company holds strong market positions in diagnostic imaging and image-guided therapy, where ongoing innovation in AI and connected systems provides a competitive edge. Philips' strategy emphasizes scaling impact through focused innovation, with a robust product pipeline targeting high-growth areas like precision diagnostics and patient monitoring. Expansion into emerging markets and e-commerce in personal health products positions it to capture demographic tailwinds from aging populations. While facing competition from peers like GE HealthCare and Siemens Healthineers, Philips' pivot to pure-play health tech enhances its structural advantages in software-enabled devices and sustainability-focused solutions.
The Q1 2026 earnings release on May 6 represents a key near-term event, where investors will scrutinize progress toward full-year guidance amid tariff uncertainties. Updates on U.S.-EU trade developments could mitigate the €250-300 million tariff hit flagged for 2026. Product launches in AI-enhanced imaging and therapy systems may drive segment growth, bolstering investor confidence in innovation execution. Analyst revisions have trended stable, with consensus price targets averaging $32.33 and ratings tilting "Overweight" from 20 analysts, reflecting cautious optimism on margin recovery. Potential regulatory clearances and partnerships in connected care could further catalyze sentiment, as Philips accelerates toward mid-single-digit comparable sales by late 2026.
The medtech industry benefits from rising global healthcare demand, fueled by aging demographics and technology adoption in AI, telehealth, and personalized care. However, Philips' trajectory is sensitive to interest rates, which influence hospital capital expenditures on imaging equipment. Inflationary pressures on components and softening China volumes—due to economic slowdowns—pose near-term challenges. Geopolitical tensions, including U.S. tariffs on medical imports, directly impact costs, though Philips seeks exemptions. Broader shifts toward value-based care and sustainability align with the company's portfolio, potentially enhancing margins if macroeconomic stabilization supports elective procedures and capex cycles.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that assists traders in identifying whether a stock, ETF, or other asset might trend bullish, bearish, or sideways over the next week or month. By analyzing vast datasets, it spots emerging trends, potential breakouts or reversals, and provides predictions across thousands of tradable instruments. Features include searchable prediction categories, historical performance context, and customizable alerts to help users stay ahead of market shifts. This neutral, data-driven resource empowers informed decision-making in dynamic markets—explore it today for actionable insights on PHG and beyond.
Philips' 2026 guidance centers on 3%-4.5% comparable sales growth, 12.5%-13% adjusted EBITA margins, and €1.3-1.5 billion in free cash flow, paving the way for mid-term 2026-2028 targets of mid-single-digit sales expansion and mid-teens profitability. Key themes include AI integration in diagnostics for efficiency gains, cost discipline amid tariffs, and market penetration in personal health via e-commerce and Gen-Z preferences. Long-term drivers encompass emerging market expansion, sustainable manufacturing transitions, and connected care ecosystems amid regulatory pushes for interoperability. Competitive threats from agile medtech innovators warrant vigilance, while capital allocation toward R&D (research and development) and selective M&A (mergers and acquisitions) will shape trajectory. Consensus expectations of 16% annual earnings growth underscore potential sentiment uplift if execution aligns with strategic priorities.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a diversified technology company, engages in providing healthcare, consumer lifestyle and lighting services
Industry MedicalNursingServices
A.I.dvisor indicates that over the last year, PHG has been loosely correlated with GEHC. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PHG jumps, then GEHC could also see price increases.
| Ticker / NAME | Correlation To PHG | 1D Price Change % | ||
|---|---|---|---|---|
| PHG | 100% | +0.46% | ||
| GEHC - PHG | 53% Loosely correlated | +1.35% | ||
| ALC - PHG | 49% Loosely correlated | +0.35% | ||
| CNMD - PHG | 46% Loosely correlated | +0.09% | ||
| ENOV - PHG | 44% Loosely correlated | +4.02% | ||
| STE - PHG | 42% Loosely correlated | +0.05% | ||
More | ||||
| Ticker / NAME | Correlation To PHG | 1D Price Change % |
|---|---|---|
| PHG | 100% | +0.46% |
| Health Services category (247 stocks) | 16% Poorly correlated | -2.67% |
| Medical/Nursing Services category (139 stocks) | 15% Poorly correlated | -3.71% |
The 10-day moving average for PHG crossed bearishly below the 50-day moving average on June 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on June 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PHG as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PHG turned negative on June 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
PHG moved below its 50-day moving average on June 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for PHG moved below the 200-day moving average on May 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PHG broke above its upper Bollinger Band on May 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PHG's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PHG advanced for three days, in of 312 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 188 cases where PHG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.919) is normal, around the industry mean (10.901). P/E Ratio (22.492) is within average values for comparable stocks, (61.230). Projected Growth (PEG Ratio) (0.850) is also within normal values, averaging (3.717). PHG has a moderately high Dividend Yield (0.039) as compared to the industry average of (0.018). P/S Ratio (1.230) is also within normal values, averaging (26.806).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PHG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.